Business Insider

Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Parkinson's Disease (PD) Patients ...

LONDON, Aug. 3, 2018 /PRNewswire/ -- Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet Neurology [1]. Treatment with APO-go ...
Business Insider

Britannia Pharmaceuticals: Landmark Apomorphine Study Confirms its Established Role as a Highly Effective Treatment for Parkinson's Disease Patients Whose Symptoms Cannot be ...

Results from the first randomized, controlled trial investigating the efficacy and safety of APO-go ® /MOVAPO ® (apomorphine) subcutaneous infusion in Parkinson's disease (PD) patients whose motor ...